01—Abstract
Summary
Summary of the 8-K filed March 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics (DGX) filed an 8-K on March 12, 2026 disclosing that its Board of Directors elected Timothy Wentworth as a new independent director, effective March 9, 2026.
Wentworth, 65, is the former CEO of Walgreens Boots Alliance, where he oversaw restructuring ahead of the company's mid-2025 sale to Sycamore Partners. He previously served as founding CEO of Evernorth Health Services (The Cigna Group) and as president and CEO of Express Scripts. The Board raised the board's size to eleven members with his addition.
He was assigned to the Compensation and Leadership Development Committee and the Quality and Compliance Committee, and the Board determined he meets NYSE independence standards. The filing is governance-focused rather than financial. It contains no earnings, guidance, or financial results.
Wentworth's compensation follows the standard non-employee director program, including a prorated one-time restricted share unit grant valued at approximately $43,000a. The press release, filed as Exhibit 99.1, quotes Chairman, CEO and President Jim Davis praising his experience across health plan, employer and consumer channels, and Lead Independent Director Timothy Ring highlighting his operational expertise in large healthcare companies. For investors, the appointment is a modest governance development.
Wentworth's experience in pharmacy benefit management, health plans and consumer health aligns with Quest's stated channels, which may be relevant to its strategy with payers and employers. The filing does not indicate any change in strategy, leadership at the executive officer level, or financial outlook.
02—Key points
Key Highlights
- Timothy Wentworth, former CEO of Walgreens Boots Alliance, was elected to Quest's Board of Directors on March 9, 2026.
- Wentworth was determined to be independent under NYSE listing standards and Quest's governance guidelines.
- He joins the Compensation and Leadership Development Committee and the Quality and Compliance Committee.
- The Board now has eleven members following his election.
- Wentworth received a prorated one-time RSU grant valued at approximately $43,000 under the non-employee director program.
- His background includes founding CEO of Evernorth Health Services and CEO of Express Scripts, relevant to Quest's payer and employer channels.
- The filing contains no financial results, guidance, or executive officer changes.
03—Questions
Frequently Asked Questions
Who is Timothy Wentworth and why was he appointed?
Timothy Wentworth, 65, is a healthcare and pharmacy benefit executive. He was most recently CEO of Walgreens Boots Alliance, previously founding CEO of Evernorth Health Services, and earlier president and CEO of Express Scripts. Quest cited his experience across health plan, employer and consumer channels and his operations and HR expertise.
Does this appointment change Quest's financial outlook?
No. The 8-K contains no financial results, guidance, or strategic changes. It is a board governance update only.
What committees will Wentworth serve on?
He was appointed to the Compensation and Leadership Development Committee and the Quality and Compliance Committee.
How is Wentworth compensated?
He receives compensation as a non-employee director under Quest's standard program. This includes a prorated one-time restricted share unit grant valued at approximately $43,000.
Is Wentworth considered independent?
Yes. The Board determined he is independent under NYSE listing standards and Quest's corporate governance guidelines.
04—Continue